While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was ...

Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing ...

Aardvark Therapeutics’ obesity asset is based on its lead molecule, which in February was linked to reversible heart safety ...

That’s not for lack of opportunity. Japan’s scientists continue to produce Nobel Prize–winning breakthroughs and the country ...

Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.

The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...

The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% ...

The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking ...

Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...

Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have ...

Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the ...

As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...